Foghorn Therapeutics (FHTX) Assets Average (2020 - 2026)

Foghorn Therapeutics' Assets Average history runs 7 years deep, the most recent figure standing at $210.1 million for Q1 2026.

• In Q1 2026, Assets Average fell 22.56% year-over-year to $210.1 million; the TTM figure through Mar 2026 stood at $210.1 million (down 22.56% YoY), while the FY2025 annual figure was $241.0 million, down 15.41% from the prior year.
• Assets Average was $210.1 million for Q1 2026 at Foghorn Therapeutics, up from $201.5 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $504.0 million in Q1 2022 to a low of $201.5 million in Q4 2025.
• Historically, Assets Average has averaged $325.3 million across 5 years, with a median of $299.7 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Assets Average jumped 125.76% in 2022, then tumbled 32.3% in 2025.
• A 5-year view of Assets Average shows it stood at $419.4 million in 2022, then decreased by 28.55% to $299.7 million in 2023, then retreated by 1.17% to $296.2 million in 2024, then slumped by 31.96% to $201.5 million in 2025, then grew by 4.27% to $210.1 million in 2026.
• The last three Assets Average figures came in at $210.1 million (Q1 2026), $201.5 million (Q4 2025), and $215.6 million (Q3 2025), per Business Quant data.